Regen Appoints President
This article was originally published in Scrip
Regen BioPharma, Inc., a publicly traded biotechnology company, has appointed Dr. Harry Lander president. Lander brings extensive experience as both a researcher and administrator to the company and has served in these positions at Cornell University and Sidra Medical and Research Centre in Qatar.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.